Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Food and Drug Administration (FDA) has granted an emergency use authorisation (EUA) for investigational convalescent plasma to treat hospitalised Covid-19 patients.
Following a review of the available scientific evidence, the regulator said that the known and potential benefits outweigh the known and potential risks of the therapy.
Clinical trials to validate safety and efficacy are ongoing. The EUA will enable distribution of Covid-19 convalescent plasma in the US and its administration by health care providers to suspected or laboratory-confirmed hospitalised patients.